Xvivo Perfusion AB (publ) (STO: XVIVO)

Market Cap	14.08B
Revenue (ttm)	750.59M
Net Income (ttm)	204.27M
Shares Out	31.50M
EPS (ttm)	6.54
PE Ratio	68.30
Forward PE	83.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,703
Open	453.50
Previous Close	452.00
Day's Range	445.50 - 461.50
52-Week Range	252.50 - 547.00
Beta	2.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a c...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 160
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XVIVO

Financial Performance

In 2023, Xvivo Perfusion AB's revenue was 597.54 million, an increase of 43.88% compared to the previous year's 415.29 million. Earnings were 91.82 million, an increase of 398.29%.